Brief: Xuanzhu Biopharmaceutical Says NG-350A Granted Fast Track Designation By U.S. FDA
28/10/2025 10:37
Oct 28 (Reuters) - Xuanzhu Biopharmaceutical Co Ltd 2575.HK: NG-350A GRANTED FAST TRACK DESIGNATION BY U.S. FDA Further company coverage: 2575.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xuanzhu Biopharmaceutical
See all newsBrief: Xuanzhu Biopharmaceutical Announces Commercial Cooperation With Innobic For Birecociclib
Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial
Brief: Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium
China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology
Brief: Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology